Primary central nervous system lymphoma treated with high-dose methotrexate and rituximab: A single-institution experience

K. Ina Ly, Laura L. Crew, Carrie A. Graham, Maciej M. Mrugala

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

Rituximab (RTX) improves the outcome in patients with systemic diffuse large B-cell lymphoma (DLBCL), but its benefit in primary central nervous system lymphoma (PCNSL) is unclear. In the present study, a single-institution retrospective analysis was performed for 12 patients with newly diagnosed PCNSL treated with combined high-dose methotrexate (HD-MTX) and RTX. MTX was administered biweekly at 8 g/m2/dose until a complete response (CR) was achieved or for a maximum of eight doses. RTX was provided for a total of eight weekly doses at 375 mg/m2/dose. Following a median of 11 cycles of MTX, the radiographic overall response rate was 91% and the CR rate was 58%. A CR was achieved after a median 6 cycles of MTX. The median progression-free survival time was 22 months and the median overall survival time has not yet been attained. These results compare favorably to single-agent HD-MTX and suggest a role for immunochemotherapy in the treatment of PCNSL.

Original languageEnglish (US)
Pages (from-to)3471-3476
Number of pages6
JournalOncology Letters
Volume11
Issue number5
DOIs
StatePublished - May 2016

Keywords

  • High-dose methotrexate
  • Non-Hodgkin's lymphoma
  • Primary central nervous system lymphoma
  • Rituximab

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Primary central nervous system lymphoma treated with high-dose methotrexate and rituximab: A single-institution experience'. Together they form a unique fingerprint.

  • Cite this